BRAF mutant inhibitors trang 1 tải miễn phí từ tailieunhanh

"BRAF mutant inhibitors" trang 1 - tải miễn phí từ tailieunhanh

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

10 43 0

Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial

Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial

8 51 0

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

11 70 1

Variations of BRAF mutant allele percentage in melanomas

Variations of BRAF mutant allele percentage in melanomas

10 30 1

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

9 32 1

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

12 54 1

An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation

An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation

11 39 1

Green does not always mean go: A sulfated galactan from Codium isthmocladum green seaweed reduc

Green does not always mean go: A sulfated galactan from Codium isthmocladum green seaweed reduc

12 12 1

NEXUS trial: A multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

NEXUS trial: A multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

7 1 1